Market Cap (In USD)
56.44 Million
Revenue (In USD)
24.35 Million
Net Income (In USD)
-65.76 Million
Avg. Volume
291.8 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.21-2.626
- PE
- -
- EPS
- -
- Beta Value
- 0.369
- ISIN
- US00032Q1040
- CUSIP
- 00032Q104
- CIK
- 1422142
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. David J. Lennon Ph.D.
- Employee Count
- -
- Website
- https://aadibio.com
- Ipo Date
- 2018-02-16
- Details
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
More Stocks
-
PKTEFParkit Enterprise Inc.
PKTEF
-
ATHHF
-
000089Shenzhen Airport Co., Ltd.
000089
-
MLFTI
-
3672AltPlus Inc.
3672
-
SAINTGOBAINSaint-Gobain Sekurit India Limited
SAINTGOBAIN
-
HIPO-WTHippo Holdings Inc. WT
HIPO-WT
-
UCSO